HFS
CRL icon

Hantz Financial Services’s Charles River Laboratories CRL Stock Holding History

Hantz Financial Services’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Buy
2,084
+932
+81% +$166K 0.01% 751
2026
Q1 		$199K Buy
1,152
+336
+41% +$62.3K ﹤0.01% 990
2025
Q4 		$163K Buy
816
+23
+3% +$4.17K ﹤0.01% 950
2025
Q3 		$124K Buy
793
+80
+11% +$12.7K ﹤0.01% 901
2025
Q2 		$108K Buy
713
+24
+3% +$3.2K ﹤0.01% 744
2025
Q1 		$104K Sell
689
-134
-16% -$22.5K ﹤0.01% 620
2024
Q4 		$152K Sell
823
-35,834
-98% -$6.9M ﹤0.01% 578
2024
Q3 		$7.22M Sell
36,657
-1,440
-4% -$299K 0.13% 178
2024
Q2 		$7.87M Sell
38,097
-1,640
-4% -$372K 0.15% 162
2024
Q1 		$10.8M Sell
39,737
-2,187
-5% -$522K 0.21% 130
2023
Q4 		$9.91M Sell
41,924
-3,208
-7% -$631K 0.22% 138
2023
Q3 		$8.85M Buy
45,132
+35
+0.1% +$7.19K 0.22% 135
2023
Q2 		$9.48M Buy
45,097
+463
+1% +$92.1K 0.24% 128
2023
Q1 		$9.01M Buy
44,634
+1,335
+3% +$303K 0.25% 130
2022
Q4 		$9.44M Buy
43,299
+1,361
+3% +$297K 0.28% 116
2022
Q3 		$8.25M Sell
41,938
-3,202
-7% -$691K 0.29% 109
2022
Q2 		$9.66M Buy
45,140
+1,193
+3% +$292K 0.33% 98
2022
Q1 		$12.5M Sell
43,947
-9,333
-18% -$2.88M 0.37% 79
2021
Q4 		$20.1M Buy
53,280
+3,312
+7% +$1.29M 0.58% 39
2021
Q3 		$20.6M Buy
49,968
+7,009
+16% +$2.91M 0.68% 33
2021
Q2 		$15.9M Buy
42,959
+2,654
+7% +$886K 0.58% 38
2021
Q1 		$11.7M Buy
40,305
+1,415
+4% +$393K 0.48% 45
2020
Q4 		$9.72M Buy
38,890
+137
+0.4% +$32.6K 0.43% 59
2020
Q3 		$8.78M Buy
38,753
+40
+0.1% +$8.3K 0.45% 55
2020
Q2 		$6.75M Buy
38,713
+896
+2% +$143K 0.38% 68
2020
Q1 		$4.77M Buy
+37,817
New +$5.67M 0.33% 85

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Hantz Financial Services's CRL Position: Q2 2026 in Review

Hantz Financial Services increased its Charles River Laboratories (CRL) stake by 81% in Q2 2026, buying an estimated $166K and bringing the position to 2,084 shares worth $473K. The position accounts for 0.01% of the portfolio, ranked #751.

Hantz Financial Services first reported a position in CRL in Q1 2020 and has held it in 26 quarters since. The position peaked at $20.6M in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Hantz Financial Services held 2,084 shares of Charles River Laboratories worth $473K as of Q2 2026.
  • Hantz Financial Services bought 932 Charles River Laboratories shares in Q2 2026, an estimated $166K.
  • Charles River Laboratories made up 0.01% of Hantz Financial Services's portfolio in Q2 2026, its #751 holding.
  • Hantz Financial Services first reported a position in Charles River Laboratories in Q1 2020 and has held it in 26 quarters since.
  • Hantz Financial Services's Charles River Laboratories position peaked at $20.6M in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.